Si-Bone Stock Price, News & Analysis

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2021 JMP Securities Life Sciences Conference. The company is set to present on June 17 at 2:30 p.m. ET. Interested parties can access a live and archived webcast on the company’s website. SI-BONE specializes in minimally invasive surgery of the SI joint with its iFuse Implant System, which has demonstrated effectiveness for treating chronic low back pain associated with sacroiliac joint dysfunction.

SI-BONE, Inc. (SIBN) reported Q1 2021 revenue of $20.4 million, marking a 22% increase from Q1 2020. U.S. revenue reached $18.8 million, up 23% year-over-year. The company launched the iFuse-TORQ implant to address pelvic trauma needs and has transitioned its leadership team, appointing Laura Francis as CEO. Operating loss narrowed to $11.6 million from $11.9 million in 2020. Despite a cautious outlook due to COVID-19, SIBN anticipates 2021 revenue of $92 million to $94 million, projecting a 25% to 28% growth.

SI-BONE, a medical device company focused on sacropelvic disorders, will participate in two key events: the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021, and the 2021 Bank of America Health Care Conference on May 12, 2021. During the Truist Securities event, management will host a Fireside Chat at 2:40 p.m. ET, and at the Bank of America Conference, they will present at 8:00 a.m. ET. Interested parties can view live and archived webcasts on the company’s website.

SI-BONE, Inc. (SIBN) announced significant leadership changes, appointing Anshul Maheshwari as Chief Financial Officer effective April 20, 2021. The transition also includes Laura Francis taking over as CEO, while Jeff Dunn remains Executive Chairman. Maheshwari brings over 15 years of experience, including his role at Varian Medical Systems. Additionally, Helen Loh and Laura Francis are new Board members, expected to enhance SI-BONE's strategy and marketing efforts. These changes aim to strengthen the company's growth and operational capabilities.

SI-BONE, Inc. (Nasdaq: SIBN) will report Q1 2021 financial results after market close on May 3, 2021. This announcement includes a conference call at 1:30 PM PT / 4:30 PM ET, accessible via phone or webcast on their website. The iFuse Implant System, the company's primary product for treating sacroiliac joint dysfunction, has shown positive clinical outcomes supported by multiple studies. Since 2009, iFuse has been the only SI joint fusion device with established insurance coverage based on its clinical effectiveness and safety.

SI-BONE, Inc. (Nasdaq:SIBN) reported financial results for Q4 and FY 2020, showcasing a 12% increase in Q4 revenue to $22.1 million and a 9% increase for the year to $73.4 million. U.S. revenue grew 10% to $68.1 million for 2020. The company expects 2021 revenue guidance of $92 million to $94 million, reflecting projected growth of 25% to 28%. Operating loss stood at $7.9 million for Q4 and $38.6 million for the year. Cash and securities totaled $196.4 million as of Dec 31, 2020. The company continues to navigate challenges posed by the COVID-19 pandemic.

SI-BONE, Inc. (Nasdaq: SIBN) will announce its financial results for Q4 and full year 2020 on March 8, 2021, after market closure. A conference call will follow at 1:30 PM PT, available via phone and webcast. The company specializes in innovative minimally invasive surgery for sacroiliac joint disorders, particularly with its iFuse Implant System, which is backed by numerous clinical studies highlighting its effectiveness. This press release underscores SI-BONE's commitment to addressing chronic low back pain issues, along with its established insurance coverage for the iFuse procedure.

SI-BONE, Inc. (SIBN) has appointed Laura Francis as Chief Executive Officer, succeeding Jeff Dunn, who transitions to Executive Chairman. Francis, previously CFO and COO, intends to focus on growth through enhancements in sales and new product development. Tony Recupero is promoted to President, Commercial Operations. Preliminary revenue for Q4 2020 is projected at $21.9-$22.2 million, marking an 11-12% increase year-over-year, while full-year revenue is expected between $73.1-$73.4 million, reflecting roughly 9% growth. However, potential COVID-19 impacts remain uncertain, and 2021 financial guidance is not provided.

SANTA CLARA, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN) announced that the International Society for the Advancement of Spine Surgery published its updated Policy on MIS Sacroiliac Joint Fusion. The policy supports the adoption of MIS SI joint fusion procedures, particularly the iFuse Procedure, based on high-level clinical evidence for its safety and effectiveness. The ISASS does not recommend MIS posterior SI joint fusion due to inadequate clinical evidence. This update provides crucial guidance for clinicians and payors regarding the iFuse Implant System.